2019
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
Serfaty L, Jacobson I, Rockstroh J, Altice FL, Hwang P, Barr E, Robertson M, Haber B. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal Of Viral Hepatitis 2019, 26: 329-336. PMID: 30412325, DOI: 10.1111/jvh.13037.Peer-Reviewed Original ResearchMeSH KeywordsAmidesAntiviral AgentsBenzofuransCarbamatesCyclopropanesData Interpretation, StatisticalFemaleGenotypeHepacivirusHepatitis C, ChronicHumansImidazolesMalePredictive Value of TestsQuinoxalinesReproducibility of ResultsSensitivity and SpecificitySulfonamidesSustained Virologic ResponseViral LoadConceptsBaseline viral loadResistance-associated substitutionsNS5A resistance-associated substitutionsEBR/GZRElbasvir/grazoprevirGenotype 1a infectionViral loadNegative predictive valuePositive predictive valuePredictive valueBaseline NS5a resistance-associated substitutionsHepatitis C virus infectionPoor negative predictive valueEuropean treatment guidelinesC virus infectionSustained virologic responseHigh positive predictive valueEBR 50GT1a infectionVirologic failureVirologic responseTreatment guidelinesTreatment outcomesVirus infectionStratification factors
2017
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes
Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, Altice FL. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. International Journal Of Drug Policy 2017, 47: 187-195. PMID: 28811159, PMCID: PMC5918282, DOI: 10.1016/j.drugpo.2017.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCoinfectionFemaleGenotypeHealth ServicesHepacivirusHepatitis CHIV InfectionsHumansInterferon-alphaMalePolyethylene GlycolsProgram DevelopmentProgram EvaluationRecombinant ProteinsRibavirinRisk FactorsSex FactorsSofosbuvirSubstance Abuse, IntravenousSustained Virologic ResponseTreatment OutcomeUkraineYoung AdultConceptsSustained virologic responseHCV treatmentRisk groupsSVR ratesMedical recordsDirect acting antiviral medicationsComparable SVR ratesHCV genotype 3HCV prevalence estimatesHCV treatment servicesActing antiviral (DAA) medicationsCombination of sofosbuvirHigh-risk groupPatient-level outcomesProportion of participantsCommunity-based settingsDAA treatmentVirologic responseAntiviral medicationsHIV characteristicsHCV genotypesIndependent correlatesSVR dataFemale sexGenotype 3
2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals Of Internal Medicine 2016, 165: 625-634. PMID: 27537841, DOI: 10.7326/m16-0816.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntiviral AgentsBenzofuransBuprenorphineBuprenorphine, Naloxone Drug CombinationDouble-Blind MethodDrug CombinationsDrug Resistance, ViralFemaleGenotypeHepatitis C, ChronicHumansImidazolesMaleMedication AdherenceMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersQuinoxalinesRecurrenceSubstance Abuse, IntravenousYoung AdultConceptsDeferred-treatment groupOpioid agonist therapyImmediate treatment groupHepatitis C virus infectionC virus infectionElbasvir-grazoprevirDrug useProbable reinfectionAgonist therapyHCV infectionViral recurrenceAdverse eventsVirus infectionChronic HCV genotype 1Double-blind trialGenotype 3 infectionTreatment-naive patientsHCV genotype 1Interferon-free HCV treatmentOngoing drug useVirologic responseHCV therapyHCV treatmentPrimary outcomeGenotype 1
2014
Epidemiological and Viral Genomic Sequence Analysis of the 2014 Ebola Outbreak Reveals Clustered Transmission
Scarpino SV, Iamarino A, Wells C, Yamin D, Ndeffo-Mbah M, Wenzel NS, Fox SJ, Nyenswah T, Altice FL, Galvani AP, Meyers LA, Townsend JP. Epidemiological and Viral Genomic Sequence Analysis of the 2014 Ebola Outbreak Reveals Clustered Transmission. Clinical Infectious Diseases 2014, 60: 1079-1082. PMID: 25516185, PMCID: PMC4375398, DOI: 10.1093/cid/ciu1131.Peer-Reviewed Original Research
2010
DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions
Altice FL, Springer SA. DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions. JAMA Internal Medicine 2010, 170: 109-110. PMID: 20065210, PMCID: PMC2825565, DOI: 10.1001/archinternmed.2009.459.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAdministration, OralAdolescentAdultAgedAnti-HIV AgentsDeoxycytidineDose-Response Relationship, DrugDrug Resistance, ViralEmtricitabineFemaleGenotypeHIV InfectionsHIV-1HumansLopinavirMaleMiddle AgedOrganophosphonatesPatient CompliancePyrimidinonesRandomized Controlled Trials as TopicRNA, ViralStavudineTenofovirTreatment OutcomeYoung Adult